Molecular Cancer

Distant origin of glioblastoma recurrence: neural stem cells in the subventricular zone serve as a source of tumor reconstruction after primary resection

Li, X., Kim, H. J., Yoo, J., Lee, Y., Nam, C. H., Park, J., … & Lee, J. H. (2025). Distant origin of glioblastoma recurrence: neural stem cells in the subventricular zone serve as a source of tumor reconstruction after primary resection. Molecular Cancer, 24(1), 64.

10.1186/s12943-025-02273-2

View Detail >

Frontiers in Oncology

The clinical relevance of surgical specimens for RNA sequencing in lung cancer: a cohort study

Eom, J. S., Kim, S. H., Kim, K., Kim, A., Ahn, H. Y., Mok, J., … & Kim, M. H. (2024). The clinical relevance of surgical specimens for RNA sequencing in lung cancer: A cohort study. Frontiers in Oncology, 14, 1462519.

10.3389/fonc.2024.1462519

View Detail >

Cancer Research and Treatment

Varlitinib and Paclitaxel for EGFR/HER2 Co-Expressing Advanced Gastric Cancer: A Multicenter Phase Ib/II Study (K-MASTER-13)

Koo DH, Jung M, Kim YH, Jeung HC, Zang DY, Bae WK, Kim H, Kim HS, Lee CK, Kwon WS, Chung HC. Varlitinib and Paclitaxel for EGFR/HER2 Co-Expressing Advanced Gastric Cancer: a Multicenter Phase Ib/II Study (K-MASTER-13). Cancer Research and Treatment. 2024 Apr 29.

10.4143/crt.2023.1324

View Detail >

Summary | celemics publications

#Oncology


#ctDNA Sample


# AlphaLiquid® 100 Panel

Purpose

Varlitinib is a pan-human epidermal growth factor receptor (HER) inhibitor targeting epidermal growth factor receptor (EGFR), HER2, and HER4. We present a phase Ib/II study of a combination of varlitinib and weekly paclitaxel as a second-line treatment for patients with EGFR/HER2 co-expressing advanced gastric cancer (AGC).

Result

Genomic alteration landscape in circulating tumor DNA analysis according to the progression-free survival (PFS), overall survival (OS), and EGFR/HER2 immunohistochemical expression (n=15).

Conclusion

A combination of varlitinib and paclitaxel displayed manageable toxicity and modest antitumor activity in patients with EGFR/HER2 co-expressing AGC who progressed after first-line chemotherapy.

Method

The circulating tumor DNA (ctDNA) was extracted from the patient’s plasma (10 mL) at two time points (before treatment and at the first response evaluation or end of the treatment). The DNA NGS library and solution-based target enrichment were performed at IMBdx, Inc. (Seoul, Korea), using AlphaLiquid100. The captured DNA libraries were sequenced using the Illumina NovaSeq 6000 platform (Illumina, San Diego, CA) in the 2×150 bp paired-end mode.

Related Product

Circulating Tumor DNA Panel for 

Colorectal / Lung / Breast Cancer

View Detail >

The circulating tumor DNA (ctDNA) was extracted from the patient’s plasma (10 mL) at two time points (before treatment and at the first response evaluation or end of the treatment). The DNA NGS library and solution-based target enrichment were performed at IMBdx, Inc. (Seoul, Korea), using AlphaLiquid100. The captured DNA libraries were sequenced using the Illumina NovaSeq 6000 platform (Illumina, San Diego, CA) in the 2×150 bp paired-end mode.

Experimental & Molecular Medicine

Synergistic toxicity with copper contributes to NAT2-associated isoniazid toxicity

Yoon JG, Jang DG, Cho SG, Lee C, Noh SH, Seo SK, Yu JW, Chung HW, Han K, Kwon SS, Han DH. Synergistic toxicity with copper contributes to NAT2-associated isoniazid toxicity. Experimental & Molecular Medicine. 2024 Mar;56(3):570-82.

10.1038/s12276-024-01172-8

View Detail >